Innovative Bahraini Deal Inked For Sickle Cell Therapy
This article was originally published in Scrip
Executive Summary
As part of a clinical collaboration agreement between the Arabian Gulf University in Bahrain and the Swedish biotech, Dilaforette AB announced Feb. 16, the Middle East University has shouldered some of the risk of developing the company's potential sickle cell therapy, sevuparin.
You may also be interested in...
Modus's Intended IPO to Spur Sickle Cell Drug R&D
The first IPO for a pharmaceutical company nurtured by Karolinska Development is expected to involve Modus Therapeutics, which has changed its name from Dilaforette and is pursuing the development of a Phase II potential sickle cell therapy.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.